Angle PLC Notice of Interim Results and Webcast
17 September 2024 - 4:00PM
RNS Regulatory News
RNS Number : 4068E
Angle PLC
17 September 2024
|
For
immediate release
|
17 September
2024
|
ANGLE plc ("the
Company")
Notice of Interim Results and
Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a
world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development
and clinical oncology, will be releasing
its interim results for the six months ended 30 June 2024 on
Thursday 26 September 2024.
A meeting for analysts will be held
at 11:00 am BST on Thursday 26 September
2024 at the offices of Berenberg, 60
Threadneedle Street, London EC2R 8HP.
A live webcast of the analyst
meeting can be accessed via ANGLE's Investor Centre page,
https://angleplc.com/investor-relations/corporate-presentations/,
with Q&A participation reserved for analysts only. Please
register in advance and log on to the webcast approximately 5
minutes before 11:00 am on the day of the results.
A recording of the webcast will be made available
on ANGLE's website following the results meeting.
For
further information:
|
ANGLE plc
|
+44
(0) 1483 343434
|
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
|
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser
|
+44
(0) 20 3207 7800
|
|
FTI
Consulting
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
For Frequently Used Terms, please
see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected CTC harvesting technology, known as the
Parsortix® PC1 system, enables complete downstream
analysis of the sample including whole cell imaging and proteomic
analysis and full genomic and transcriptomic molecular
analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Diagnostic
products include the Parsortix® system and associated
consumables. The clinical services business is offered through
ANGLE's GCLP-compliant laboratories in the UK. Services
include custom made assay development and clinical trial testing
for pharma.
Over 90 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit www.angleplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORBRGDCDDBDGSL
Angle (LSE:AGL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Angle (LSE:AGL)
Historical Stock Chart
From Dec 2023 to Dec 2024
